Teva Pharmaceutical Industries, Ltd. et al. v. Eli Lilly & Company
Infringement action filed 27 Sep 2018 in the United States District Court for the District of Massachusetts and closed 28 Sep 2023, with 9 patents asserted. Recorded basis of termination: judgment on the merits for defendant.
Case record
- Patents involved
- US9890210B2US9340614B2US9266951B2US9346881B2US9884908B2US8597649B2US9884907B2US9890211B2US8586045B2
- Case no.
- 1:18-cv-12029
- Verdict cause
- Infringement action
- Court
- D. Mass.
- Court level
- District Court
- Case region
- Massachusetts
- Chief judge
- Allison D. Burroughs
- Trial level
- First instance
- Filed – Closed
- 27 Sep 2018 – 28 Sep 2023
- Duration
- 1827 days
- Basis of termination
- Judgment on the merits for Defendant
- Products & marks
- Galcanezumab a humanized monoclonal antibody · LY2951742
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Antagonist antibodies directed against calcitonin gene-related peptide
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
- Legal status
- Inactive
- Granted
- 13 Feb 2018
- Earliest priority
- 2 Nov 2006
- Est. expiry
- 2 Nov 2026
- Validity challenges
- 1 on recordIPR2018-01425 · filed by Eli Lilly and Company
- Licences recorded
- None recorded
- Inventors
- ZELLER, JOERG · POULSEN, KRISTIAN T. · ABDICHE, YASMINA NOUBIA · PONS, JAUME · COLLIER, SIERRA JONES · ROSENTHAL, ARNON
- Classification
- A61K39/395C12P21/08C07K16/18A61K39/00
- Prosecution counsel
- FISH & RICHARDSON P.C.
- Examiner
- SAOUD, CHRISTINE J
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
- Legal status
- Active
- Granted
- 17 May 2016
- Earliest priority
- 2 Nov 2006
- Est. expiry
- 2 Nov 2026
- Validity challenges
- 1 on recordIPR2018-01422 · filed by Eli Lilly and Company
- Licences recorded
- None recorded
- Inventors
- ZELLER, JOERG · POULSEN, KRISTIAN T. · ABDICHE, YASMINA NOUBIA · PONS, JAUME · COLLIER, SIERRA JONES · ROSENTHAL, ARNON
- Classification
- A61K39/395C07K16/26C07K16/00C12P21/08A61K39/00A61K31/4045C07K16/18
- Prosecution counsel
- FISH & RICHARDSON P.C.
- Examiner
- SAOUD, CHRISTINE J
Also asserted in this case
7 moreThe docket lists 9 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining 7 asserted patents are one query away in Eureka.
- US9266951B2Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
- US9346881B2Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
- US9884908B2Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
- US8597649B2Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
- US9884907B2Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
- US9890211B2Antagonist antibodies directed against calcitonin gene-related peptide
- US8586045B2Methods of using anti-CGRP antagonist antibodies
Parties of record
Teva Pharmaceutical Industries, Ltd.
- Core tech
- Not recorded
- Counsel
- Alexandra Lu · Douglas J. Kline · Elaine Herrmann Blais · Eric T. Romeo · I. Neel Chatterjee · Joshua S. Weinger · Kathleen A. McGuiness · Kevin P. Martin · Martin C. Topol · Molly Grammel · Natasha E. Daughtrey · Robert Frederickson III · Shaobo Zhu · Tara Rose Thigpen
- Firm
- Allen & Overy LLP, Goodwin Procter LLP, Preti Flaherty, LLP
- Also named
- Teva Pharmaceuticals USA, Inc.
Eli Lilly & Company
- Core tech
- Not recorded
- Counsel
- Amana Abdulwakeel · Andrea L. Martin · Charles E. Lipsey · Daniel F. Roland · Danielle A. Duszczyszyn, I · Denise Main · Emily R. Gabranski · J. Michael Jakes · Li Zhang · Mark J. Stewart · Marta Garcia Daneshvar · Matthew J Luneack · Oulu Wang · Pier D. DeRoo · Ryan P. O’Quinn · Sanjay M. Jivraj · William B. Raich · Yoonjin Lee
- Firm
- Burns & Levinson LLP, Eli Lilly And Company, Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Counsel of record
Basis of termination
From the record · verbatim“Defendant Eli Lilly and Company’s favor”
Case 1:18-cv-12029 · D. Mass. · closed 28 September 2023
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 1:18-cv-12029?
1:18-cv-12029 is a patent infringement action brought by Teva Pharmaceutical Industries, Ltd. against Eli Lilly & Company, filed on 27 Sep 2018 in the United States District Court for the District of Massachusetts. The case closed on 28 September 2023.
Which patents were asserted in 1:18-cv-12029?
US9890210B2 (“Antagonist antibodies directed against calcitonin gene-related peptide”), assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH, currently inactive; US9340614B2 (“Antagonist antibodies directed against calcitonin gene-related peptide and methods using same”), assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH, currently active; US9266951B2 (“Antagonist antibodies directed against calcitonin gene-related peptide and methods using same”), assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH; US9346881B2 (“Antagonist antibodies directed against calcitonin gene-related peptide and methods using same”), assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH; US9884908B2 (“Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide”), assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH; US8597649B2 (“Antagonist antibodies directed against calcitonin gene-related peptide and methods using same”), assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH; US9884907B2 (“Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide”), assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH; US9890211B2 (“Antagonist antibodies directed against calcitonin gene-related peptide”), assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH; US8586045B2 (“Methods of using anti-CGRP antagonist antibodies”), assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH. The record also lists Galcanezumab a humanized monoclonal antibody and LY2951742.
How was case 1:18-cv-12029 terminated?
The recorded basis of termination is judgment on the merits for defendant. The termination text reads: “Defendant Eli Lilly and Company’s favor”
What does judgment on the merits mean?
A judgment on the merits decides the substance of the claims, as opposed to ending the case on procedural grounds.
How long did case 1:18-cv-12029 take?
1827 calendar days, from filing on 27 Sep 2018 to closure on 28 September 2023.
Who were the attorneys and the judge in 1:18-cv-12029?
Chief Judge Allison D. Burroughs presided. Alexandra Lu, Douglas J. Kline, Elaine Herrmann Blais, Eric T. Romeo, I. Neel Chatterjee, Joshua S. Weinger, Kathleen A. McGuiness, Kevin P. Martin, Martin C. Topol, Molly Grammel, Natasha E. Daughtrey, Robert Frederickson III, Shaobo Zhu and Tara Rose Thigpen are recorded as counsel for plaintiff Teva Pharmaceutical Industries. Amana Abdulwakeel, Andrea L. Martin, Charles E. Lipsey, Daniel F. Roland, Danielle A. Duszczyszyn, I, Denise Main, Emily R. Gabranski, J. Michael Jakes, Li Zhang, Mark J. Stewart, Marta Garcia Daneshvar, Matthew J Luneack, Oulu Wang, Pier D. DeRoo, Ryan P. O’Quinn, Sanjay M. Jivraj, William B. Raich and Yoonjin Lee appear for defendant Eli Lilly &.
Disclaimer. This page reproduces publicly available court docket data for case 1:18-cv-12029 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.